Update: Pavel Buchnevich and Adam Fox on COVID list, Tarmo Reunanen expected to debut

adam fox
Mar 6, 2021; Newark, New Jersey, USA; New York Rangers center Ryan Strome (16) celebrates his third period goal against the New Jersey Devils at Prudential Center. Mandatory Credit: Ed Mulholland-USA TODAY Sports

The latest NHL COVID list has just come out and the Rangers have added both Pavel Buchnevich and Adam Fox to it. That helps explain the call up of Tarmo Reunanen.

The question now begs to be asked if Reunanen will indeed be getting the start in Fox’s place. More on this soon.

https://twitter.com/FriedgeHNIC/status/1371574718604718081?s=20

Tarmo Reunanen called up

UPDATE: Tarmo Reunanen expected to debut

The Rangers 22 year-old left handed defenseman from Finland, didn’t have a great camp. At the same time it was an abbreviated one with not even a single exhibition game.

Tarmo Reunanen however has picked up where he left off in Liiga. He’s using his size and hockey sense to lead the Wolf Pack blue line. Thus far in four games for Hartford he has 2 goals and 4 points without a single penalty.

Tarmo Reunanen
Tarmo Reunanen (NHLI/Getty Images)

The name Tarmo Reunanen was not one many New York Rangers fans knew much of back in 2016. Selected 98th overall in the fourth round, only prospect connoisseurs were aware he existed.

“I have no idea about the schedule but I am ready to leave immediately when everything is clear and I get the call from the Rangers,” he told Forever Blueshirts back in October. Reunanen did indeed come to camp but it didn’t work out as he likely planned.

Still the Rangers saw it fit to keep him in Hartford and he’s been impressive. Similar to how he was playing in Finland before coming over. He’s getting big minutes and not afraid to step up offensively. He’s been a steady contributor for the Blueshirts’ AHL affiliate.

Anthony Scultore is the founder of Forever Blueshirts and has been covering the New York Rangers and the NHL... More about Anthony Scultore

Mentioned in this article:

More About: